Dr Garon on Challenges Associated With Immunotherapy Use in EGFR-mutated NSCLC

Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.

Related Keywords

China ,Los Angeles ,California ,United States ,Aaron Lisberg ,Edwardb Garon ,Division Of Hematology Oncology ,University Of California ,David Geffen School Of Medicine ,Department Of Medicine ,David Geffen School ,Non Small Cell Lung Cancer ,Pd L1 And Ctla 4 Inhibitor ,Egfr Mutated Nsclc ,Immunotherapy ,Angiogenic Inhibitor ,